Xenetic partner wins Israeli health ministry clearance for DNase I plus anti-CD19 CAR-T lymphoma study

Xenetic Biosciences, Inc.
Ethos Technologies

Xenetic Biosciences, Inc.

XBIO

0.00

Ethos Technologies

LIFE

0.00
  • Xenetic Biosciences’ partner PeriNess secured Israeli Health Ministry clearance for an investigator-initiated DNase I plus anti-CD19 CAR T study in LBCL.
  • Trial targets 12 patients with stable or progressive disease at lymphodepletion, aiming to test whether DNase I improves CAR T expansion and response.
  • Study will run at Tel-Aviv Sourasky Medical Center, with initial efficacy readouts planned at 1 and 3 months post-infusion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenetic Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202606040840ACCESSWRNAPR_____1172877) on June 04, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.